论文部分内容阅读
目的探讨依达拉奉联合丹红注射液治疗急性脑梗死的临床疗效。方法将94例急性脑梗死患者随机分为治疗组和对照组,各47例,两组均给予抗血小板聚集、控制血压、预防感染等对症治疗,治疗组加用依达拉奉联合丹红注射液治疗,对照组给予丹红注射液治疗,采用NIHSS评分评定神经功能缺损程度,采用Barthel指数评定日常生活活动能力(ADL),并观察临床疗效。结果治疗组总有效率为91.49%,对照组为72.34%,治疗组疗效优于对照组(P<0.05)。结论在常规治疗的基础上,联合应用依达拉奉和丹红注射液治疗脑梗死患者安全有效。
Objective To investigate the clinical efficacy of edaravone combined with Danhong injection in the treatment of acute cerebral infarction. Methods 94 patients with acute cerebral infarction were randomly divided into treatment group and control group, 47 cases in each group. Both groups were given anti-platelet aggregation, blood pressure control, infection prevention and other symptomatic treatment. The treatment group was treated with edaravone combined with Danhong injection The patients in the control group were treated with Danhong injection. NIHSS score was used to assess the degree of neurological deficit. The Barthel index was used to assess the activity of daily living (ADL), and the clinical efficacy was observed. Results The total effective rate was 91.49% in the treatment group and 72.34% in the control group. The curative effect in the treatment group was better than that in the control group (P <0.05). Conclusion On the basis of routine treatment, the combination of edaravone and Danhong injection in the treatment of patients with cerebral infarction safe and effective.